FDA Determines Regulatory Review Period for Baxdela Tablets Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Baxdela Tablets, a prescription medication, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO)